Methotrexate

Generic Name: Methotrexate

Brand Names: Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₅

CAS Number: 59-05-2

Unique Ingredient Identifier: YL5FZ2Y5U1

Background: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication: Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis

Associated Therapies: Medically induced abortion

Clinical Trials

Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium

Phase 3

Completed

Conditions: Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: doxorubicin hydrochloride
Drug: gemcitabine hydrochloride
Drug: vinblastine sulfate
Drug: methotrexate
Drug: cisplatin
Biological: filgrastim

First Posted Date: 2003-01-27

Last Posted Date: 2016-08-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 285

Registration Number: NCT00028756

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: cytarabine
Drug: prednisone
Drug: methotrexate
Drug: prednisolone
Drug: etoposide
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1148

Registration Number: NCT00002757

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧
Children's Hospital - Sheffield, Sheffield, England, United Kingdom

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: dactinomycin
Biological: sargramostim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: etoposide
Drug: mercaptopurine
Drug: prednisone
Drug: mitoxantrone hydrochloride
Drug: pegaspargase
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-02-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 170

Registration Number: NCT00002766

Locations: 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 4 locations

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 179

Registration Number: NCT00003650

Locations: 🇫🇷
Centre Leon Berard, Lyon, France

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Phase 3

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2011-01-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1500

Registration Number: NCT00003728

Locations: 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹
Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷
CHR de Besancon - Hopital Saint-Jacques, Besancon, France

and more 20 locations

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2023-07-05

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 59

Registration Number: NCT00003910

Locations: 🇺🇸
Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
McFarland Clinic, PC, Ames, Iowa, United States

and more 65 locations

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00002792

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Phase 2

Terminated

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 10

Registration Number: NCT00041288

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States

and more 20 locations

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Phase 2

Terminated

Conditions: Cardiac Toxicity
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-06-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00019864

Locations: 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

and more 1 locations

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005802

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy